Atossa Genetics Inc. (NASDAQ:ATOS) Given Average Recommendation of “Hold” by Analysts

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have been assigned an average rating of “Hold” from the five ratings firms that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $6.3333.

A number of analysts have recently issued reports on ATOS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Atossa Genetics in a research note on Wednesday, October 8th. Zacks Research downgraded shares of Atossa Genetics from a “hold” rating to a “strong sell” rating in a report on Monday, October 13th. Finally, Ascendiant Capital Markets increased their price target on Atossa Genetics from $7.75 to $8.00 and gave the stock a “buy” rating in a research note on Monday, December 8th.

Atossa Genetics Stock Up 6.9%

ATOS stock opened at $0.63 on Monday. The business’s 50-day moving average price is $0.77 and its 200-day moving average price is $0.83. The stock has a market cap of $81.45 million, a P/E ratio of -2.63 and a beta of 1.09. Atossa Genetics has a twelve month low of $0.55 and a twelve month high of $1.29.

Atossa Genetics (NASDAQ:ATOS) last released its earnings results on Wednesday, November 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). On average, equities research analysts expect that Atossa Genetics will post -0.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Ameriprise Financial Inc. bought a new position in Atossa Genetics in the 2nd quarter worth approximately $2,468,000. Jane Street Group LLC purchased a new position in shares of Atossa Genetics in the second quarter worth $381,000. Y Intercept Hong Kong Ltd bought a new position in shares of Atossa Genetics during the second quarter worth $321,000. Qube Research & Technologies Ltd boosted its position in shares of Atossa Genetics by 357.4% during the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock worth $346,000 after acquiring an additional 325,340 shares during the last quarter. Finally, GSA Capital Partners LLP grew its stake in Atossa Genetics by 509.0% during the third quarter. GSA Capital Partners LLP now owns 310,754 shares of the company’s stock valued at $269,000 after acquiring an additional 259,725 shares in the last quarter. 12.74% of the stock is owned by hedge funds and other institutional investors.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.